Skip to content
Assyro AI

FDA letters by response type

Warning Letter FDA Letters

Serious post-market compliance violation. Browse source-linked warning letter records with structured metadata, regulatory context, and document-level summaries.

FDA regulatory letters with type, issue date, agency, product, and status
LetterTypeIssuedAgency / ProductStatus
Warning Letter Eherbs Imports, Inc (Jul 23, 2026)

FDA issued a warning letter to Eherbs Imports, Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter mkpodplug.co.uk (Jul 17, 2026)

FDA issued a warning letter to mkpodplug.co.uk concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter San Jorge Produce LLC (Jul 16, 2026)

FDA issued a warning letter to San Jorge Produce LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Island Kinetics, Inc. d.b.a. CoValence Laboratories (Jul 16, 2026)

FDA issued a warning letter to Island Kinetics, Inc. d.b.a. CoValence Laboratories concerning CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Labeling, claims, and misbranding, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated

Open
Warning Letter BioMylz Pvt. Ltd. (Jul 13, 2026)

FDA issued a warning letter to BioMylz Pvt. Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated/Misbranded

Open
Warning Letter Almon Healthcare Private Limited (Jul 13, 2026)

FDA issued a warning letter to Almon Healthcare Private Limited concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter Shimoga Chemicals (Jul 13, 2026)

FDA issued a warning letter to Shimoga Chemicals concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Data integrity and records, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter indejuicevapestore.co.uk (Jul 10, 2026)

FDA issued a warning letter to indejuicevapestore.co.uk concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. (Jul 10, 2026)

FDA issued a warning letter to Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. concerning In Vivo Bioavailability-Bioequivalence Studies – Clinical. Deterministic source-metadata screening identifies discussion of Clinical research and human-subject protections. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

In Vivo Bioavailability-Bioequivalence Studies – Clinical

Open
Warning Letter ejuicedemand.com (Jul 10, 2026)

FDA issued a warning letter to ejuicedemand.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter VasoCorp, Inc. (Jul 9, 2026)

FDA issued a warning letter to VasoCorp, Inc. concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Beauty Store LLC (Jul 8, 2026)

FDA issued a warning letter to Beauty Store LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Spa De Soleil, Inc. (Jul 8, 2026)

FDA issued a warning letter to Spa De Soleil, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter IJAJ Group Inc DBA Sanz Wholesale Foods (Jul 8, 2026)

FDA issued a warning letter to IJAJ Group Inc DBA Sanz Wholesale Foods concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter International Medication Systems Limited (Jul 2, 2026)

FDA issued a warning letter to International Medication Systems Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter eliquidflavourconcentrates.co.uk (Jul 2, 2026)

FDA issued a warning letter to eliquidflavourconcentrates.co.uk concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter snusblast.co.uk (Jul 2, 2026)

FDA issued a warning letter to snusblast.co.uk concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Piquin Y Sabores Distributors LLC (Jul 2, 2026)

FDA issued a warning letter to Piquin Y Sabores Distributors LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Balkanica LLC (Jun 29, 2026)

FDA issued a warning letter to Balkanica LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Excelvision - Fareva (Jun 25, 2026)

FDA issued a warning letter to Excelvision - Fareva concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Wizcure Pharmaa Private Limited (Jun 24, 2026)

FDA issued a warning letter to Wizcure Pharmaa Private Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Win Woo Trading, LLC / HF Foods Group (Jun 24, 2026)

FDA issued a warning letter to Win Woo Trading, LLC / HF Foods Group concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter LyfeUnit / www.lyfeunit.com (Jun 23, 2026)

FDA issued a warning letter to LyfeUnit / www.lyfeunit.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Ketamine Troche Store / www.ketaminetrochestore.com (Jun 23, 2026)

FDA issued a warning letter to Ketamine Troche Store / www.ketaminetrochestore.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com (Jun 23, 2026)

FDA issued a warning letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Med Shop Inc / www.medshopinc.com (Jun 23, 2026)

FDA issued a warning letter to Med Shop Inc / www.medshopinc.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Allandale Dairy (Jun 23, 2026)

FDA issued a warning letter to Allandale Dairy concerning New Animal Drug/Adulterated. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Animal Drug/Adulterated

Open
Warning Letter Keta Med Lab / www.ketamedlab.com (Jun 23, 2026)

FDA issued a warning letter to Keta Med Lab / www.ketamedlab.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Legit Ketamine Suppliers / www.legitketaminesuppliers.com (Jun 23, 2026)

FDA issued a warning letter to Legit Ketamine Suppliers / www.legitketaminesuppliers.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Extra Medication / www.extramedication.com (Jun 23, 2026)

FDA issued a warning letter to Extra Medication / www.extramedication.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Ketacyn Pharmaceuticals / www.ketacynpharma.com (Jun 23, 2026)

FDA issued a warning letter to Ketacyn Pharmaceuticals / www.ketacynpharma.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter ketaminetroches.com (Jun 23, 2026)

FDA issued a warning letter to ketaminetroches.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Ketdaxandrugs / www.ketdaxandrugs.org (Jun 23, 2026)

FDA issued a warning letter to Ketdaxandrugs / www.ketdaxandrugs.org concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Ket Plug / ketaminelab.org and buyketaminepowderonline.com (Jun 23, 2026)

FDA issued a warning letter to Ket Plug / ketaminelab.org and buyketaminepowderonline.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Buy Keta Online / www.buyketaonline.com (Jun 23, 2026)

FDA issued a warning letter to Buy Keta Online / www.buyketaonline.com concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter All Ketamine HCL / www.allketaminehcl.com (Jun 23, 2026)

FDA issued a warning letter to All Ketamine HCL / www.allketaminehcl.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Ketamine Store / www.ketaminestore.org (Jun 23, 2026)

FDA issued a warning letter to Ketamine Store / www.ketaminestore.org concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Genzyme Ireland Limited (Jun 22, 2026)

FDA issued a warning letter to Genzyme Ireland Limited concerning CGMP/Deviations/Biologics License Application (BLA). Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Deviations/Biologics License Application (BLA)

Open
Warning Letter Texinkart Inc. (Jun 17, 2026)

FDA issued a warning letter to Texinkart Inc. concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Herbal Dermals LLC FZ dba Gotucream (Jun 17, 2026)

FDA issued a warning letter to Herbal Dermals LLC FZ dba Gotucream concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Hadassah Healing Oils Ltd (Jun 17, 2026)

FDA issued a warning letter to Hadassah Healing Oils Ltd concerning Unapproved New Drugs. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs

Open
Warning Letter Telos Trading Limited dba Alwinshop (Jun 17, 2026)

FDA issued a warning letter to Telos Trading Limited dba Alwinshop concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Leading Edge Health Inc. (Jun 17, 2026)

FDA issued a warning letter to Leading Edge Health Inc. concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Amazon.com, Inc. (Jun 17, 2026)

FDA issued a warning letter to Amazon.com, Inc. concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Wild Arabic Herbs (Jun 17, 2026)

FDA issued a warning letter to Wild Arabic Herbs concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Indiangoods.shop (Jun 17, 2026)

FDA issued a warning letter to Indiangoods.shop concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Great India Overseas Pvt. Ltd. dba Silkrute (Jun 17, 2026)

FDA issued a warning letter to Great India Overseas Pvt. Ltd. dba Silkrute concerning Unapproved New Drugs. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs

Open
Warning Letter Wholesale Peptide (Jun 17, 2026)

FDA issued a warning letter to Wholesale Peptide concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter MantroForce (Jun 17, 2026)

FDA issued a warning letter to MantroForce concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter JJLBRO (Jun 17, 2026)

FDA issued a warning letter to JJLBRO concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Diamond Distributions LLC (Jun 16, 2026)

FDA issued a warning letter to Diamond Distributions LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Life & Food Inc. (Jun 15, 2026)

FDA issued a warning letter to Life & Food Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Happiest Baby, Inc. (Jun 15, 2026)

FDA issued a warning letter to Happiest Baby, Inc. concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

Open
Warning Letter Huons Co., Ltd. (Jun 15, 2026)

FDA issued a warning letter to Huons Co., Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Quality systems and CAPA, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Yangzhou Hongshengding Chemical Co., Ltd. (Jun 15, 2026)

FDA issued a warning letter to Yangzhou Hongshengding Chemical Co., Ltd. concerning Refusal to Provide Access to and Copying of Records. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Refusal to Provide Access to and Copying of Records

Open
Warning Letter AHC Products, Inc. (Jun 12, 2026)

FDA issued a warning letter to AHC Products, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Labeling, claims, and misbranding, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Nihon Kohden Digital Health Solutions, LLC (Jun 12, 2026)

FDA issued a warning letter to Nihon Kohden Digital Health Solutions, LLC concerning Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)

Open
Warning Letter Maximus Health, Inc. dba Maximus (Jun 8, 2026)

FDA issued a warning letter to Maximus Health, Inc. dba Maximus concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Medica Weight Loss (Jun 8, 2026)

FDA issued a warning letter to Medica Weight Loss concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter HydraMed IV LLC dba HydraMed (Jun 8, 2026)

FDA issued a warning letter to HydraMed IV LLC dba HydraMed concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter FITISH (Jun 8, 2026)

FDA issued a warning letter to FITISH concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Momentum Health 360 dba Momentum Health (Jun 8, 2026)

FDA issued a warning letter to Momentum Health 360 dba Momentum Health concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Ezra Holdco LLC dba Ezra (Jun 8, 2026)

FDA issued a warning letter to Ezra Holdco LLC dba Ezra concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Nova Vascular LLC dba NOVARX (Jun 8, 2026)

FDA issued a warning letter to Nova Vascular LLC dba NOVARX concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter NativeMed LLC dba NativeMed (Jun 8, 2026)

FDA issued a warning letter to NativeMed LLC dba NativeMed concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Delight Distribution Inc. (Jun 8, 2026)

FDA issued a warning letter to Delight Distribution Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter OrderlyMeds LLC dba OrderlyMeds (Jun 8, 2026)

FDA issued a warning letter to OrderlyMeds LLC dba OrderlyMeds concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Eden Health International Inc. dba Eden (Jun 8, 2026)

FDA issued a warning letter to Eden Health International Inc. dba Eden concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter D&H Medical Services (Jun 8, 2026)

FDA issued a warning letter to D&H Medical Services concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Roen Health, Inc. dba RoenRx (Jun 8, 2026)

FDA issued a warning letter to Roen Health, Inc. dba RoenRx concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Trinity HealthCare Supply, LLC dba altRx (Jun 8, 2026)

FDA issued a warning letter to Trinity HealthCare Supply, LLC dba altRx concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Vivot LLC (Jun 8, 2026)

FDA issued a warning letter to Vivot LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Altru Telehealth, LLC dba Altru Telehealth (Jun 8, 2026)

FDA issued a warning letter to Altru Telehealth, LLC dba Altru Telehealth concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Nexlife Inc. dba Nexlife (Jun 8, 2026)

FDA issued a warning letter to Nexlife Inc. dba Nexlife concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Public Health Solution LLC dba DrMedHealth (Jun 8, 2026)

FDA issued a warning letter to Public Health Solution LLC dba DrMedHealth concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter VivioMD Group LLC dba VivioMD (Jun 8, 2026)

FDA issued a warning letter to VivioMD Group LLC dba VivioMD concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Ready Med (Jun 8, 2026)

FDA issued a warning letter to Ready Med concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Joi and Blokes dba Joi + Blokes (Jun 8, 2026)

FDA issued a warning letter to Joi and Blokes dba Joi + Blokes concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Amie Health, Inc. dba Amie (Jun 8, 2026)

FDA issued a warning letter to Amie Health, Inc. dba Amie concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Nexus Health Solutions LLC dba Harper Meds (Jun 8, 2026)

FDA issued a warning letter to Nexus Health Solutions LLC dba Harper Meds concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Clover Meds LLC dba Clover Meds (Jun 8, 2026)

FDA issued a warning letter to Clover Meds LLC dba Clover Meds concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter FitRX, LLC dba AM RX (Jun 8, 2026)

FDA issued a warning letter to FitRX, LLC dba AM RX concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter YS Group Inc. (Jun 8, 2026)

FDA issued a warning letter to YS Group Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Thrivelab Co. dba Thrivelab (Jun 8, 2026)

FDA issued a warning letter to Thrivelab Co. dba Thrivelab concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Glow Medispa, LLC dba Mint Med (Jun 8, 2026)

FDA issued a warning letter to Glow Medispa, LLC dba Mint Med concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Imu-Tek Animal Health, Incorporated (Jun 5, 2026)

FDA issued a warning letter to Imu-Tek Animal Health, Incorporated concerning Dietary Supplement/New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Dietary Supplement/New Drug/Misbranded

Open
Warning Letter Mineral BioSciences, LLC (Jun 5, 2026)

FDA issued a warning letter to Mineral BioSciences, LLC concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Sante Manufacturing Inc. (Jun 5, 2026)

FDA issued a warning letter to Sante Manufacturing Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter AseptiKits, LLC (Jun 4, 2026)

FDA issued a warning letter to AseptiKits, LLC concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

Open
Warning Letter Nutratech, LLC (Jun 4, 2026)

FDA issued a warning letter to Nutratech, LLC concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated/Misbranded

Open
Warning Letter BlephEx, LLC (Jun 3, 2026)

FDA issued a warning letter to BlephEx, LLC concerning Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Deterministic full-text screening identifies discussion of Quality systems and CAPA, Labeling, claims, and misbranding, Medical device quality and reporting, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)

Open
Warning Letter Hubei Gedian Humanwell Pharmaceutical Co., Ltd. (Jun 3, 2026)

FDA issued a warning letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd. concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter InvaDerm, Inc. (Jun 3, 2026)

FDA issued a warning letter to InvaDerm, Inc. concerning Electronic Drug Registration and Listing System (eDRLS)/Violations. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Electronic Drug Registration and Listing System (eDRLS)/Violations

Open
Warning Letter M G R Produce LLC (Jun 2, 2026)

FDA issued a warning letter to M G R Produce LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter PLZ Corp (Jun 2, 2026)

FDA issued a warning letter to PLZ Corp concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Gopaldas Visram & Co., Ltd. (Jun 2, 2026)

FDA issued a warning letter to Gopaldas Visram & Co., Ltd. concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter SL Follen Company (Jun 2, 2026)

FDA issued a warning letter to SL Follen Company concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Zydus Lifesciences Limited (Jun 2, 2026)

FDA issued a warning letter to Zydus Lifesciences Limited concerning Request for Records/CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Request for Records/CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Umendra Life Sciences Private Limited (Jun 2, 2026)

FDA issued a warning letter to Umendra Life Sciences Private Limited concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Shantou Qiwei Industry Co., LTD (Jun 2, 2026)

FDA issued a warning letter to Shantou Qiwei Industry Co., LTD concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Erkul Kozmetik Sanayi ve Ticaret A.S. (Jun 2, 2026)

FDA issued a warning letter to Erkul Kozmetik Sanayi ve Ticaret A.S. concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Revlon Group Holdings, LLC (Jun 2, 2026)

FDA issued a warning letter to Revlon Group Holdings, LLC concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Laboratorios Dr. Collado S.A. (Jun 2, 2026)

FDA issued a warning letter to Laboratorios Dr. Collado S.A. concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Asanuma Corporation - Sagamihara Factory (Jun 2, 2026)

FDA issued a warning letter to Asanuma Corporation - Sagamihara Factory concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Macau-Union Pharmaceutical Limited (May 29, 2026)

FDA issued a warning letter to Macau-Union Pharmaceutical Limited concerning Nonprescription/OTC. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter Jubilant HollisterStier General Partnership (May 28, 2026)

FDA issued a warning letter to Jubilant HollisterStier General Partnership concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Manufacturing and CGMP controls, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Medline Inc (May 28, 2026)

FDA issued a warning letter to Medline Inc concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Manufacturing and CGMP controls, Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Jose M. Carpio, M.D. (May 28, 2026)

FDA issued a warning letter to Jose M. Carpio, M.D. concerning Clinical Investigator. Deterministic full-text screening identifies discussion of Clinical research and human-subject protections, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator

Open
Warning Letter Pharmathen International S.A. (May 27, 2026)

FDA issued a warning letter to Pharmathen International S.A. concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Manufacturing and CGMP controls, Laboratory controls and testing, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter Linemaster Switch Corporation (May 27, 2026)

FDA issued a warning letter to Linemaster Switch Corporation concerning CGMP/QSR/Drug/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Drug/Medical Devices/Adulterated

Open
Warning Letter AF Import & Wholesale Co (May 26, 2026)

FDA issued a warning letter to AF Import & Wholesale Co concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Blue Horizon International, LLC (May 26, 2026)

FDA issued a warning letter to Blue Horizon International, LLC concerning Unapproved New Drugs/Unlicensed Biological Product Violations. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Unlicensed Biological Product Violations

Open
Warning Letter Pamex Foods Incorporated (May 26, 2026)

FDA issued a warning letter to Pamex Foods Incorporated concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter ZIIP, Inc. (May 22, 2026)

FDA issued a warning letter to ZIIP, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Labeling, claims, and misbranding, Medical device quality and reporting, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Laboratorios Jaloma S.A. de C.V. (May 22, 2026)

FDA issued a warning letter to Laboratorios Jaloma S.A. de C.V. concerning CGMP/OTC/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Aeroflex Industria de Aerosol Ltda. (May 22, 2026)

FDA issued a warning letter to Aeroflex Industria de Aerosol Ltda. concerning Refusal to Provide Access to and Copying of Records. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Refusal to Provide Access to and Copying of Records

Open
Warning Letter Alchymars ICM SM Private Limited (May 21, 2026)

FDA issued a warning letter to Alchymars ICM SM Private Limited concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter BMC Medical Co., Ltd. (May 20, 2026)

FDA issued a warning letter to BMC Medical Co., Ltd. concerning CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Unapproved products and premarket authorization, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded

Open
Warning Letter Aversa's Italian Bakery (May 20, 2026)

FDA issued a warning letter to Aversa's Italian Bakery concerning CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Food safety and supplier verification, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated

Open
Warning Letter Golden Dakota Farms LLC (May 20, 2026)

FDA issued a warning letter to Golden Dakota Farms LLC concerning New Animal Drug/Adulterated. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Animal Drug/Adulterated

Open
Warning Letter 3B Medical, Inc. dba Reach Health, Inc. (May 20, 2026)

FDA issued a warning letter to 3B Medical, Inc. dba Reach Health, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter vapetrinity.com (May 19, 2026)

FDA issued a warning letter to vapetrinity.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter HealthPartners Neuroscience Center Research and Innovation (May 19, 2026)

FDA issued a warning letter to HealthPartners Neuroscience Center Research and Innovation concerning Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Deterministic full-text screening identifies discussion of Data integrity and records, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

Open
Warning Letter snusguys.com (May 19, 2026)

FDA issued a warning letter to snusguys.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter npouches.com (May 19, 2026)

FDA issued a warning letter to npouches.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter pouchline.com (May 19, 2026)

FDA issued a warning letter to pouchline.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Skytron, LLC (May 19, 2026)

FDA issued a warning letter to Skytron, LLC concerning Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)

Open
Warning Letter pouchew.com (May 19, 2026)

FDA issued a warning letter to pouchew.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Smoker Business (May 19, 2026)

FDA issued a warning letter to Smoker Business concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter vapenovaco.com (May 19, 2026)

FDA issued a warning letter to vapenovaco.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter gethyppe.com (May 19, 2026)

FDA issued a warning letter to gethyppe.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter GSC Products, LLC (May 18, 2026)

FDA issued a warning letter to GSC Products, LLC concerning Nonprescription/OTC. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter Sato Pharmaceutical Co., Ltd. (May 18, 2026)

FDA issued a warning letter to Sato Pharmaceutical Co., Ltd. concerning CGMP/Drugs/Adulterated/OTC. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Drugs/Adulterated/OTC

Open
Warning Letter Aja Health and Wellness Inc. (May 18, 2026)

FDA issued a warning letter to Aja Health and Wellness Inc. concerning Nonprescription/OTC. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter vape4sale.com (May 15, 2026)

FDA issued a warning letter to vape4sale.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Meta Labs Pharmaceuticals, LLC (May 15, 2026)

FDA issued a warning letter to Meta Labs Pharmaceuticals, LLC concerning Dietary Supplement/New Drug/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Dietary Supplement/New Drug/Misbranded

Open
Warning Letter City Market, Inc. (May 15, 2026)

FDA issued a warning letter to City Market, Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter La Crema De Rebeca (May 14, 2026)

FDA issued a warning letter to La Crema De Rebeca concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Bharat Overseas Inc. (May 14, 2026)

FDA issued a warning letter to Bharat Overseas Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter GC America, Inc. (May 14, 2026)

FDA issued a warning letter to GC America, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Quality systems and CAPA, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter PolleyMed, LLC (May 14, 2026)

FDA issued a warning letter to PolleyMed, LLC concerning Nonprescription/OTC. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter Lus Essentials LLC (May 14, 2026)

FDA issued a warning letter to Lus Essentials LLC concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Bushman Organic Farms, Inc. (May 14, 2026)

FDA issued a warning letter to Bushman Organic Farms, Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Dough-To-Go, Inc. (May 12, 2026)

FDA issued a warning letter to Dough-To-Go, Inc. concerning CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated

Open
Warning Letter Flax & More Corporation (May 12, 2026)

FDA issued a warning letter to Flax & More Corporation concerning CGMP/Dietary Supplement/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated

Open
Warning Letter Fagron BV (May 12, 2026)

FDA issued a warning letter to Fagron BV concerning Compounding Pharmacy/Adulterated Drug Products. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter ct-riecig.com (May 8, 2026)

FDA issued a warning letter to ct-riecig.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter waterbedsnstuff.com (May 8, 2026)

FDA issued a warning letter to waterbedsnstuff.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Naseem A. Jaffrani, M.D. (May 4, 2026)

FDA issued a warning letter to Naseem A. Jaffrani, M.D. concerning Clinical Investigator. Deterministic source-metadata screening identifies discussion of Clinical research and human-subject protections. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator

Open
Warning Letter IDO Pharm Co., Ltd. (May 4, 2026)

FDA issued a warning letter to IDO Pharm Co., Ltd. concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Naveh Pharma LTD/Bigdam Inc. (May 4, 2026)

FDA issued a warning letter to Naveh Pharma LTD/Bigdam Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Quality systems and CAPA, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

Open
Warning Letter Harbin Jixianglong Biotech Co., Ltd. (May 1, 2026)

FDA issued a warning letter to Harbin Jixianglong Biotech Co., Ltd. concerning CGMP/API/Adulterated and Misbranded Drugs. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/API/Adulterated and Misbranded Drugs

Open
Warning Letter kadobarofficial.com (May 1, 2026)

FDA issued a warning letter to kadobarofficial.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter swisschlz.com (May 1, 2026)

FDA issued a warning letter to swisschlz.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter CareFusion 213, LLC (Apr 30, 2026)

FDA issued a warning letter to CareFusion 213, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter ZOLL Medical Corporation (Apr 30, 2026)

FDA issued a warning letter to ZOLL Medical Corporation concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Best Buy Bones, Inc. (Apr 30, 2026)

FDA issued a warning letter to Best Buy Bones, Inc. concerning CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food for Animals (PCAF)/Adulterated. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food for Animals (PCAF)/Adulterated

Open
Warning Letter OptiHealth Products, Inc. (Apr 29, 2026)

FDA issued a warning letter to OptiHealth Products, Inc. concerning New Drug/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Drug/Misbranded

Open
Warning Letter Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre (Apr 29, 2026)

FDA issued a warning letter to Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre concerning In Vivo Bioavailability-Bioequivalence Studies – Clinical. Deterministic full-text screening identifies discussion of Clinical research and human-subject protections, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

In Vivo Bioavailability-Bioequivalence Studies – Clinical

Open
Warning Letter Sourav K. Mishra, M.D. / All India Institute of Medical Sciences (Apr 29, 2026)

FDA issued a warning letter to Sourav K. Mishra, M.D. / All India Institute of Medical Sciences concerning In Vivo Bioavailability-Bioequivalence Studies – Clinical. Deterministic full-text screening identifies discussion of Clinical research and human-subject protections, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

In Vivo Bioavailability-Bioequivalence Studies – Clinical

Open
Warning Letter Sahara Enterprise Inc. (Apr 29, 2026)

FDA issued a warning letter to Sahara Enterprise Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Shineluck Foods, Inc. (Apr 29, 2026)

FDA issued a warning letter to Shineluck Foods, Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated/L. monocytogenes. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated/L. monocytogenes

Open
Warning Letter Greenworld Food Express LLC (Apr 24, 2026)

FDA issued a warning letter to Greenworld Food Express LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter vibepixi.com (Apr 24, 2026)

FDA issued a warning letter to vibepixi.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Ray’s Vitamins (Apr 24, 2026)

FDA issued a warning letter to Ray’s Vitamins concerning Unapproved New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drug/Misbranded

Open
Warning Letter ibeautistore.com (Apr 24, 2026)

FDA issued a warning letter to ibeautistore.com concerning Unapproved New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drug/Misbranded

Open
Warning Letter Great One Trading Inc. (Apr 24, 2026)

FDA issued a warning letter to Great One Trading Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Global Imports Origins (Apr 23, 2026)

FDA issued a warning letter to Global Imports Origins concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter jadepouch.com (Apr 23, 2026)

FDA issued a warning letter to jadepouch.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Minh Phung, Inc. (Apr 22, 2026)

FDA issued a warning letter to Minh Phung, Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter Active Cosmetics Manufacturing Inc. (Apr 22, 2026)

FDA issued a warning letter to Active Cosmetics Manufacturing Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Laboratory controls and testing, Manufacturing and CGMP controls, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Estar Technologies Ltd (Apr 22, 2026)

FDA issued a warning letter to Estar Technologies Ltd concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

Open
Warning Letter Boba Factory Inc (Apr 22, 2026)

FDA issued a warning letter to Boba Factory Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Daily Manufacturing Solutions Inc. (Apr 21, 2026)

FDA issued a warning letter to Daily Manufacturing Solutions Inc. concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Foshan Miwei Cosmetics Co., Ltd. (Apr 20, 2026)

FDA issued a warning letter to Foshan Miwei Cosmetics Co., Ltd. concerning Nonprescription/OTC. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter Respilon Production S.R.O. (Apr 20, 2026)

FDA issued a warning letter to Respilon Production S.R.O. concerning CGMP/OTC/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC/Finished Pharmaceuticals/Adulterated

Open
Warning Letter SaNOtize (Apr 17, 2026)

FDA issued a warning letter to SaNOtize concerning Unapproved New Drugs. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs

Open
Warning Letter nicoprof.com (Apr 17, 2026)

FDA issued a warning letter to nicoprof.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Great Enterprise - Group - Inc. (Apr 17, 2026)

FDA issued a warning letter to Great Enterprise - Group - Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Par Health USA, LLC & Endo USA, Inc. (Apr 15, 2026)

FDA issued a warning letter to Par Health USA, LLC & Endo USA, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Hangzhou Yiqi Biotechnology Co., Ltd (Apr 15, 2026)

FDA issued a warning letter to Hangzhou Yiqi Biotechnology Co., Ltd concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter Unetixs Vascular, Inc. (Apr 15, 2026)

FDA issued a warning letter to Unetixs Vascular, Inc. concerning Premarket Approval/Adulterated. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Quality systems and CAPA, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Premarket Approval/Adulterated

Open
Warning Letter Stavis Seafoods, LLC (Apr 15, 2026)

FDA issued a warning letter to Stavis Seafoods, LLC concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter JW Nutritional LLC (Apr 15, 2026)

FDA issued a warning letter to JW Nutritional LLC concerning CGMP/OTC Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/OTC Finished Pharmaceuticals/Adulterated

Open
Warning Letter Pro Numb Tattoo Numbing Spray, LLC (Apr 14, 2026)

FDA issued a warning letter to Pro Numb Tattoo Numbing Spray, LLC concerning Nonprescription/OTC. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter New Life Pharma LLC (Apr 14, 2026)

FDA issued a warning letter to New Life Pharma LLC concerning CGMP/Adulterated and Unapproved New Drug/Misbranded. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Adulterated and Unapproved New Drug/Misbranded

Open
Warning Letter Ava Inc. (Apr 14, 2026)

FDA issued a warning letter to Ava Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter UCSF Radiopharmaceutical Facility (Apr 13, 2026)

FDA issued a warning letter to UCSF Radiopharmaceutical Facility concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter shopcalismokes.com (Apr 10, 2026)

FDA issued a warning letter to shopcalismokes.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Fareva Amboise (Apr 10, 2026)

FDA issued a warning letter to Fareva Amboise concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Data integrity and records, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Prida Import & Export LLC (Apr 10, 2026)

FDA issued a warning letter to Prida Import & Export LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Full Fresh Produce LLC (Apr 10, 2026)

FDA issued a warning letter to Full Fresh Produce LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Medical Products Laboratories, Inc. (Apr 9, 2026)

FDA issued a warning letter to Medical Products Laboratories, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

Open
Warning Letter vapepengood.com (Apr 9, 2026)

FDA issued a warning letter to vapepengood.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter The Wilatta Group Inc. (Apr 8, 2026)

FDA issued a warning letter to The Wilatta Group Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Chemco Corporation (Apr 7, 2026)

FDA issued a warning letter to Chemco Corporation concerning Nonprescription/OTC. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Quality systems and CAPA, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Nonprescription/OTC

Open
Warning Letter Nature’s Elements, Inc. (Apr 7, 2026)

FDA issued a warning letter to Nature’s Elements, Inc. concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated/Misbranded

Open
Warning Letter ProRx LLC (Apr 7, 2026)

FDA issued a warning letter to ProRx LLC concerning Compounding Pharmacy/Adulterated Drug Products. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter Smart Vending Services, LLC (Apr 7, 2026)

FDA issued a warning letter to Smart Vending Services, LLC concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Lexia LLC (Apr 7, 2026)

FDA issued a warning letter to Lexia LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Labeling, claims, and misbranding, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter mohawksmoke.com (Apr 3, 2026)

FDA issued a warning letter to mohawksmoke.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter The Fish Aid (Apr 3, 2026)

FDA issued a warning letter to The Fish Aid concerning Unapproved New Animal Drug Products. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Animal Drug Products

Open
Warning Letter Ridley USA Inc. (Apr 3, 2026)

FDA issued a warning letter to Ridley USA Inc. concerning CGMP/Medicated Feeds/Adulterated. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Medicated Feeds/Adulterated

Open
Warning Letter DK Hardware Supply (Apr 3, 2026)

FDA issued a warning letter to DK Hardware Supply concerning Unapproved New Animal Drug Products. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Animal Drug Products

Open
Warning Letter Purolea Cosmetics Lab (Apr 2, 2026)

FDA issued a warning letter to Purolea Cosmetics Lab concerning CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Laboratory controls and testing, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

Open
Warning Letter Beauty of Aztlan LLC (Apr 2, 2026)

FDA issued a warning letter to Beauty of Aztlan LLC concerning Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet

Open
Warning Letter Rxgoodusa (Apr 1, 2026)

FDA issued a warning letter to Rxgoodusa concerning Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet

Open
Warning Letter Online Rx Medz (Apr 1, 2026)

FDA issued a warning letter to Online Rx Medz concerning Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet

Open
Warning Letter Dry Springs Pharmacy (Apr 1, 2026)

FDA issued a warning letter to Dry Springs Pharmacy concerning Notice of Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Notice of Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet

Open
Warning Letter Pure Indulgence Aesthetics (Apr 1, 2026)

FDA issued a warning letter to Pure Indulgence Aesthetics concerning Drug Supply Chain Security Act (DSCSA) Violations. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Drug Supply Chain Security Act (DSCSA) Violations

Open
Warning Letter Zap Expo Center Inc. (Mar 31, 2026)

FDA issued a warning letter to Zap Expo Center Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter PekCura Labs (Mar 31, 2026)

FDA issued a warning letter to PekCura Labs concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Gram Peptides (Mar 31, 2026)

FDA issued a warning letter to Gram Peptides concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Global Tobacco, LLC (Mar 31, 2026)

FDA issued a warning letter to Global Tobacco, LLC concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter FormPour (Mar 31, 2026)

FDA issued a warning letter to FormPour concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Guangzhou Huli Technology Co., Ltd. dba Fantasy Face (Mar 31, 2026)

FDA issued a warning letter to Guangzhou Huli Technology Co., Ltd. dba Fantasy Face concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Lovega LLC dba Pink Pony Peptides (Mar 31, 2026)

FDA issued a warning letter to Lovega LLC dba Pink Pony Peptides concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Mile High Compounds LLC (Mar 31, 2026)

FDA issued a warning letter to Mile High Compounds LLC concerning Unapproved New Drugs Sold Over the Internet. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter Prime Sciences (Mar 31, 2026)

FDA issued a warning letter to Prime Sciences concerning Unapproved New Drugs Sold Over the Internet. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs Sold Over the Internet

Open
Warning Letter DO&CO Aktiengesellschaft/DO&CO, Inc. (Mar 30, 2026)

FDA issued a warning letter to DO&CO Aktiengesellschaft/DO&CO, Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated/L. monocytogenes. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Food safety and supplier verification, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated/L. monocytogenes

Open
Warning Letter Intas Pharmaceuticals Limited (Mar 30, 2026)

FDA issued a warning letter to Intas Pharmaceuticals Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Laboratory controls and testing, Quality systems and CAPA, Manufacturing and CGMP controls, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Ehsan Sadri, M.D. (Mar 27, 2026)

FDA issued a warning letter to Ehsan Sadri, M.D. concerning Clinical Investigator. Deterministic source-metadata screening identifies discussion of Clinical research and human-subject protections. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator

Open
Warning Letter buydeltas.com (Mar 27, 2026)

FDA issued a warning letter to buydeltas.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Baja Fresko Distributors Inc. (Mar 27, 2026)

FDA issued a warning letter to Baja Fresko Distributors Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter J&B Food Consulting (Mar 27, 2026)

FDA issued a warning letter to J&B Food Consulting concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Eaglelionton Int'l Trading Co Inc (Mar 26, 2026)

FDA issued a warning letter to Eaglelionton Int'l Trading Co Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Henan Lvyuan Pharmaceutical Co. Ltd. (Mar 26, 2026)

FDA issued a warning letter to Henan Lvyuan Pharmaceutical Co. Ltd. concerning CGMP/API/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/API/Adulterated

Open
Warning Letter Medline Industries, LP (Mar 25, 2026)

FDA issued a warning letter to Medline Industries, LP concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Xiamen Kang Zhongyuan Biotechnology Co., Ltd. (Mar 23, 2026)

FDA issued a warning letter to Xiamen Kang Zhongyuan Biotechnology Co., Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Data integrity and records, Manufacturing and CGMP controls, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Nupack Inc. (Mar 20, 2026)

FDA issued a warning letter to Nupack Inc. concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated/Misbranded

Open
Warning Letter matesbrand.com (Mar 20, 2026)

FDA issued a warning letter to matesbrand.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter RC Outsourcing, LLC (Mar 20, 2026)

FDA issued a warning letter to RC Outsourcing, LLC concerning Compounding Pharmacy/Adulterated Drug Products. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter Shang Hao Jia, Inc. (Mar 18, 2026)

FDA issued a warning letter to Shang Hao Jia, Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Yangzhou H&R Plastic Daily Chemical Co., Ltd. (Mar 18, 2026)

FDA issued a warning letter to Yangzhou H&R Plastic Daily Chemical Co., Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Schlechter Farms Inc. (Mar 18, 2026)

FDA issued a warning letter to Schlechter Farms Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter 4U Health (Mar 17, 2026)

FDA issued a warning letter to 4U Health concerning Premarket Approval/Adulterated. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Premarket Approval/Adulterated

Closed
Warning Letter Microbiological Testing & Consulting, LLC (Mar 16, 2026)

FDA issued a warning letter to Microbiological Testing & Consulting, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Data integrity and records, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter ImmunityBio, Inc. (Mar 13, 2026)

FDA issued a warning letter to ImmunityBio, Inc. concerning False & Misleading Claims/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded

Open
Warning Letter Patcos Cosmetics Pvt. Ltd. (Mar 12, 2026)

FDA issued a warning letter to Patcos Cosmetics Pvt. Ltd. concerning Finished Drug Products/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Quality systems and CAPA, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Finished Drug Products/Adulterated

Open
Warning Letter Adnan Dahdul, MD (Mar 12, 2026)

FDA issued a warning letter to Adnan Dahdul, MD concerning Clinical Investigator/BIMO. Deterministic full-text screening identifies discussion of Clinical research and human-subject protections, Quality systems and CAPA, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator/BIMO

Open
Warning Letter ISA Produce Corporation (Mar 12, 2026)

FDA issued a warning letter to ISA Produce Corporation concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter OraLabs, Inc. (Mar 11, 2026)

FDA issued a warning letter to OraLabs, Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Flowchem Pharma Private Limited (Mar 11, 2026)

FDA issued a warning letter to Flowchem Pharma Private Limited concerning CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Open
Warning Letter Vedic Lifesciences Pvt. Ltd. (Mar 9, 2026)

FDA issued a warning letter to Vedic Lifesciences Pvt. Ltd. concerning Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

Open
Warning Letter JZ Wholesale, Inc. (Mar 9, 2026)

FDA issued a warning letter to JZ Wholesale, Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter Espifresh Inc. (Mar 6, 2026)

FDA issued a warning letter to Espifresh Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Half Hill Farm Inc. (Mar 6, 2026)

FDA issued a warning letter to Half Hill Farm Inc. concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter prilla.com/us (Mar 6, 2026)

FDA issued a warning letter to prilla.com/us concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Life Plus Style Gourmet LLC (Mar 5, 2026)

FDA issued a warning letter to Life Plus Style Gourmet LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter SSS AUSTAR LLC (Mar 5, 2026)

FDA issued a warning letter to SSS AUSTAR LLC concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Novo Nordisk Inc. (Mar 5, 2026)

FDA issued a warning letter to Novo Nordisk Inc. concerning Postmarketing Adverse Drug Experience Reporting Requirements. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Data integrity and records. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Postmarketing Adverse Drug Experience Reporting Requirements

Open
Warning Letter Citra100mg (Mar 4, 2026)

FDA issued a warning letter to Citra100mg concerning Unapproved New Drugs/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Misbranded

Open
Warning Letter Fareva Morton Grove (Mar 3, 2026)

FDA issued a warning letter to Fareva Morton Grove concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Ocean Group Inc. (Mar 3, 2026)

FDA issued a warning letter to Ocean Group Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Quality systems and CAPA, Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Simtra BioPharma Solutions (Mar 3, 2026)

FDA issued a warning letter to Simtra BioPharma Solutions concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Barcelona Nut Company Inc. (Mar 3, 2026)

FDA issued a warning letter to Barcelona Nut Company Inc. concerning CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter Tentamus India Private Limited (Mar 3, 2026)

FDA issued a warning letter to Tentamus India Private Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Laboratory controls and testing, Data integrity and records, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter NSE Products, Inc. DBA Nu Skin Enterprises, Inc. (Mar 2, 2026)

FDA issued a warning letter to NSE Products, Inc. DBA Nu Skin Enterprises, Inc. concerning Electronic Drug Registration and Listing System (eDRLS)/Violations. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Electronic Drug Registration and Listing System (eDRLS)/Violations

Closed
Warning Letter thesnuslife.com (Feb 27, 2026)

FDA issued a warning letter to thesnuslife.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter snushaven.com (Feb 27, 2026)

FDA issued a warning letter to snushaven.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter idripejuice.com (Feb 27, 2026)

FDA issued a warning letter to idripejuice.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Rio Verde Food Service Inc. (Feb 27, 2026)

FDA issued a warning letter to Rio Verde Food Service Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Longhorn Vaccines and Diagnostics LLC (Feb 26, 2026)

FDA issued a warning letter to Longhorn Vaccines and Diagnostics LLC concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Trangs Group USA Incorporated (Feb 24, 2026)

FDA issued a warning letter to Trangs Group USA Incorporated concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter IsoTis OrthoBiologics, Inc. (Feb 24, 2026)

FDA issued a warning letter to IsoTis OrthoBiologics, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Genesis Health International Inc. dba Genesis (Feb 20, 2026)

FDA issued a warning letter to Genesis Health International Inc. dba Genesis concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Peaks Curative, LLC dba Peaks (Feb 20, 2026)

FDA issued a warning letter to Peaks Curative, LLC dba Peaks concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Join Josie (Feb 20, 2026)

FDA issued a warning letter to Join Josie concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Kin Meds (Feb 20, 2026)

FDA issued a warning letter to Kin Meds concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Premium Health Management Inc. dba Premium Health (Feb 20, 2026)

FDA issued a warning letter to Premium Health Management Inc. dba Premium Health concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics (Feb 20, 2026)

FDA issued a warning letter to Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Levity Inc. dba Levity (Feb 20, 2026)

FDA issued a warning letter to Levity Inc. dba Levity concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Ivim Services LLC dba Ivim (Feb 20, 2026)

FDA issued a warning letter to Ivim Services LLC dba Ivim concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter PharmaZee (Feb 20, 2026)

FDA issued a warning letter to PharmaZee concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Weightless Medical LLC dba WeightCare (Feb 20, 2026)

FDA issued a warning letter to Weightless Medical LLC dba WeightCare concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Newman Clinic, PLLC dba Newman Clinic (Feb 20, 2026)

FDA issued a warning letter to Newman Clinic, PLLC dba Newman Clinic concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Lean Rx, Inc. dba SkinnyRx (Feb 20, 2026)

FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Better Health Labs, Inc. dba Measured (Feb 20, 2026)

FDA issued a warning letter to Better Health Labs, Inc. dba Measured concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter MEDVi, LLC dba MEDVi (Feb 20, 2026)

FDA issued a warning letter to MEDVi, LLC dba MEDVi concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Alan Health Technologies Inc. dba Alan (Feb 20, 2026)

FDA issued a warning letter to Alan Health Technologies Inc. dba Alan concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Refills Health, LLC dba Refills Health (Feb 20, 2026)

FDA issued a warning letter to Refills Health, LLC dba Refills Health concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter FitRX, LLC dba FitRx (Feb 20, 2026)

FDA issued a warning letter to FitRX, LLC dba FitRx concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Zeuss LLC dba Zeuss (Feb 20, 2026)

FDA issued a warning letter to Zeuss LLC dba Zeuss concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Strut Health, LLC dba Strut (Feb 20, 2026)

FDA issued a warning letter to Strut Health, LLC dba Strut concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Kare Solutions, LLC dba Zappy (Feb 20, 2026)

FDA issued a warning letter to Kare Solutions, LLC dba Zappy concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Viv Health, Inc. dba VIV RX (Feb 20, 2026)

FDA issued a warning letter to Viv Health, Inc. dba VIV RX concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Good Girl LLC dba GoodGirlRX (Feb 20, 2026)

FDA issued a warning letter to Good Girl LLC dba GoodGirlRX concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Bliv Wellness LLC dba Bliv (Feb 20, 2026)

FDA issued a warning letter to Bliv Wellness LLC dba Bliv concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter NewSelf Limited dba NewSelf (Feb 20, 2026)

FDA issued a warning letter to NewSelf Limited dba NewSelf concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter 24HrDoc, Inc. dba 24HrDoc (Feb 20, 2026)

FDA issued a warning letter to 24HrDoc, Inc. dba 24HrDoc concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Belle Health LLC dba Belle (Feb 20, 2026)

FDA issued a warning letter to Belle Health LLC dba Belle concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Dripgym Mobile Parent, LLC dba Amp Health (Feb 20, 2026)

FDA issued a warning letter to Dripgym Mobile Parent, LLC dba Amp Health concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter BluefitMD (Feb 20, 2026)

FDA issued a warning letter to BluefitMD concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter MaxLife Technologies Inc. dba Maxlife (Feb 20, 2026)

FDA issued a warning letter to MaxLife Technologies Inc. dba Maxlife concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter Aspen Aesthetics dba Fifty 410 (Feb 20, 2026)

FDA issued a warning letter to Aspen Aesthetics dba Fifty 410 concerning False & Misleading Claims/Misbranded (Telehealth). Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded (Telehealth)

Open
Warning Letter El Rey USA Meats & Seafood Inc. (Feb 19, 2026)

FDA issued a warning letter to El Rey USA Meats & Seafood Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter JMT Inter LLC (Feb 19, 2026)

FDA issued a warning letter to JMT Inter LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Raw Bistro Inc. (Feb 17, 2026)

FDA issued a warning letter to Raw Bistro Inc. concerning CGMP/Food for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Food for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter The Sabagh Group Inc/lighterusa.com (Feb 13, 2026)

FDA issued a warning letter to The Sabagh Group Inc/lighterusa.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter swedishproducts.online (Feb 13, 2026)

FDA issued a warning letter to swedishproducts.online concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter AQ USA Inc., d.b.a Ross Healthcare Inc. (Feb 12, 2026)

FDA issued a warning letter to AQ USA Inc., d.b.a Ross Healthcare Inc. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Black Sheep Egg Company, LLC (Feb 12, 2026)

FDA issued a warning letter to Black Sheep Egg Company, LLC concerning PHS Act/Shell Egg Regulation/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

PHS Act/Shell Egg Regulation/Adulterated

Open
Warning Letter A. Nelson & Co. Ltd. (Feb 12, 2026)

FDA issued a warning letter to A. Nelson & Co. Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Data integrity and records, Quality systems and CAPA, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Dynamic Stem Cell Therapy (Feb 11, 2026)

FDA issued a warning letter to Dynamic Stem Cell Therapy concerning Unapproved New Drugs/Unlicensed Biological Product Violations. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs/Unlicensed Biological Product Violations

Open
Warning Letter ProDx Health (Feb 10, 2026)

FDA issued a warning letter to ProDx Health concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Open
Warning Letter Hearthy Foods, Inc. (Feb 10, 2026)

FDA issued a warning letter to Hearthy Foods, Inc. concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated/Misbranded

Open
Warning Letter A TO Z Distributor Inc (Feb 10, 2026)

FDA issued a warning letter to A TO Z Distributor Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic full-text screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Thrive Health and Wellness, LLC dba Thrive Health Solutions (Feb 9, 2026)

FDA issued a warning letter to Thrive Health and Wellness, LLC dba Thrive Health Solutions concerning Compounding Pharmacy/Adulterated Drug Products. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter Cosmetic Manufacturers Pty Ltd. (Feb 6, 2026)

FDA issued a warning letter to Cosmetic Manufacturers Pty Ltd. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter ExThera Medical Corporation (Feb 6, 2026)

FDA issued a warning letter to ExThera Medical Corporation concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic full-text screening identifies discussion of Clinical research and human-subject protections, Labeling, claims, and misbranding, Unapproved products and premarket authorization, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Open
Warning Letter Bio-Medical Pharmaceutical Manufacturing Corporation (Feb 5, 2026)

FDA issued a warning letter to Bio-Medical Pharmaceutical Manufacturing Corporation concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Beach Weekend Management LLC dba Nic and Jet Fuel (Feb 5, 2026)

FDA issued a warning letter to Beach Weekend Management LLC dba Nic and Jet Fuel concerning Unapproved New Drugs. Deterministic full-text screening identifies discussion of Tobacco product authorization and marketing, Labeling, claims, and misbranding, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Unapproved New Drugs

Open
Warning Letter Mark S. Dacey, M.D. (Feb 2, 2026)

FDA issued a warning letter to Mark S. Dacey, M.D. concerning Clinical Investigator. Deterministic source-metadata screening identifies discussion of Clinical research and human-subject protections. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator

Open
Warning Letter Apollo Care, LLC (Feb 2, 2026)

FDA issued a warning letter to Apollo Care, LLC concerning Compounding Pharmacy/Adulterated Drug Products. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter Bertrand P. Cole, D.O. (Feb 2, 2026)

FDA issued a warning letter to Bertrand P. Cole, D.O. concerning Clinical Investigator. Deterministic source-metadata screening identifies discussion of Clinical research and human-subject protections. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Clinical Investigator

Open
Warning Letter gotpouches.com (Jan 30, 2026)

FDA issued a warning letter to gotpouches.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Cohance Lifesciences Limited (Jan 30, 2026)

FDA issued a warning letter to Cohance Lifesciences Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter niqpouches.com (Jan 30, 2026)

FDA issued a warning letter to niqpouches.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter Central Coast Multispecialty Medical Group, Inc. (Jan 29, 2026)

FDA issued a warning letter to Central Coast Multispecialty Medical Group, Inc. concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)

Open
Warning Letter Fidelity Melon, Inc (Jan 29, 2026)

FDA issued a warning letter to Fidelity Melon, Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Diasol, Inc. (Jan 29, 2026)

FDA issued a warning letter to Diasol, Inc. concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Open
Warning Letter Beta Bionics, Inc. (Jan 28, 2026)

FDA issued a warning letter to Beta Bionics, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Beta Bionics, Inc. (Jan 28, 2026)

FDA issued a warning letter to Beta Bionics, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Flextronics America LLC (Jan 27, 2026)

FDA issued a warning letter to Flextronics America LLC concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Manufacturing and CGMP controls, Medical device quality and reporting, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Conceive Fertility Center (Jan 27, 2026)

FDA issued a warning letter to Conceive Fertility Center concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). Deterministic full-text screening identifies discussion of Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)

Open
Warning Letter HTO Nevada, Inc. dba Kirkman (Jan 27, 2026)

FDA issued a warning letter to HTO Nevada, Inc. dba Kirkman concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Abbott Diabetes Care, Inc. (Jan 23, 2026)

FDA issued a warning letter to Abbott Diabetes Care, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Intelligent Remedies, Inc. (Jan 23, 2026)

FDA issued a warning letter to Intelligent Remedies, Inc. concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Drug/Misbranded

Open
Warning Letter Louisville Reproductive Center (Jan 23, 2026)

FDA issued a warning letter to Louisville Reproductive Center concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)

Open
Warning Letter Tombak LLC (Jan 22, 2026)

FDA issued a warning letter to Tombak LLC concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

Open
Warning Letter South Bay Cold Storage & Handling, Inc. (Jan 22, 2026)

FDA issued a warning letter to South Bay Cold Storage & Handling, Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Diamond-Herpanacine of PA, Inc. (Jan 22, 2026)

FDA issued a warning letter to Diamond-Herpanacine of PA, Inc. concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Drug/Misbranded

Open
Warning Letter Supersmart USA, LLC (Jan 21, 2026)

FDA issued a warning letter to Supersmart USA, LLC concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

New Drug/Misbranded

Open
Warning Letter Signature Formulations, LLC (Jan 21, 2026)

FDA issued a warning letter to Signature Formulations, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Naumes, Inc. (Jan 21, 2026)

FDA issued a warning letter to Naumes, Inc. concerning Food/Prepared Packed or Held Under Insanitary Conditions/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Food/Prepared Packed or Held Under Insanitary Conditions/Adulterated

Open
Warning Letter GenoGenix LLC (Jan 20, 2026)

FDA issued a warning letter to GenoGenix LLC concerning Compounding Pharmacy/Adulterated Drug Products. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter East CK Trading Inc. (Jan 16, 2026)

FDA issued a warning letter to East CK Trading Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Zip Foods Importers, Inc (Jan 16, 2026)

FDA issued a warning letter to Zip Foods Importers, Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Feng Foods Trading Inc. (Jan 16, 2026)

FDA issued a warning letter to Feng Foods Trading Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Boothwyn Pharmacy, LLC (Jan 16, 2026)

FDA issued a warning letter to Boothwyn Pharmacy, LLC concerning Compounding Pharmacy/Adulterated Drug Products. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Compounding Pharmacy/Adulterated Drug Products

Open
Warning Letter The Great Smart African Food LLC (Jan 15, 2026)

FDA issued a warning letter to The Great Smart African Food LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Foreign Supplier Verification Program (FSVP)

Open
Warning Letter Fulijaya Manufacturing SDN. BHD. (Jan 14, 2026)

FDA issued a warning letter to Fulijaya Manufacturing SDN. BHD. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open
Warning Letter Min Jiang Food Store Inc dba Koi Koi Trading (Jan 14, 2026)

FDA issued a warning letter to Min Jiang Food Store Inc dba Koi Koi Trading concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Manufacturing and CGMP controls, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions

Open
Warning Letter Center For Immunology Science, LLC (Jan 13, 2026)

FDA issued a warning letter to Center For Immunology Science, LLC concerning Sponsor/Investigator. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Sponsor/Investigator

Open
Warning Letter CC Pollen Company (Jan 9, 2026)

FDA issued a warning letter to CC Pollen Company concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Dietary Supplement/Adulterated/Misbranded

Open
Warning Letter Germaphobix (Jan 9, 2026)

FDA issued a warning letter to Germaphobix concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Closed
Warning Letter Christopher Dale Butler (Jan 9, 2026)

FDA issued a warning letter to Christopher Dale Butler concerning Acidified Foods/Emergency Permit Control/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Acidified Foods/Emergency Permit Control/Adulterated

Open
Warning Letter Prodrome Sciences USA, LLC (Jan 8, 2026)

FDA issued a warning letter to Prodrome Sciences USA, LLC concerning Sponsor/Unapproved Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Sponsor/Unapproved Misbranded

Open
Warning Letter Genovate (Jan 8, 2026)

FDA issued a warning letter to Genovate concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Open
Warning Letter Unomedical Device S.A. de C.V. (Jan 8, 2026)

FDA issued a warning letter to Unomedical Device S.A. de C.V. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/QSR/Medical Devices/Adulterated

Open
Warning Letter Elanco Animal Health USA (Jan 8, 2026)

FDA issued a warning letter to Elanco Animal Health USA concerning False & Misleading Claims/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

False & Misleading Claims/Misbranded

Open
Warning Letter Genetrace (Jan 8, 2026)

FDA issued a warning letter to Genetrace concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

Open
Warning Letter Winder Laboratories, LLC (Jan 7, 2026)

FDA issued a warning letter to Winder Laboratories, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

WL

US FDA

CGMP/Finished Pharmaceuticals/Adulterated

Open